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1  |  INTRODUC TION
Lennox-Gastaut syndrome (LGS) is among the most severe epileptic 
and developmental encephalopathies. LGS arises in childhood with 
an onset between 18 months and 8 years of age, and most often 
between 3 and 5 years of age.1 LGS accounts for about 3% to 5% of 
all childhood epilepsies.2,3
LGS is characterized by the occurrence of multiple drug-resistant 
seizure types, characteristic slow spike-and-wave electroencepha-
logram activity, and usually cognitive impairment and behavioral 
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Objectives: Lennox-Gastaut syndrome (LGS) is among the most severe epileptic and 
developmental encephalopathies. A meta-analysis was performed to evaluate the ef-
fectiveness of adjunctive vagus nerve stimulation (VNS Therapy) in patients with LGS.
Materials & Methods: PubMed database was queried (January 1997 to September 
2018) to identify publications reporting on the efficacy of VNS Therapy in patients 
with LGS, with or without safety findings. Primary endpoint of the meta-analysis was 
the proportion of responders (≥50% reduction in seizure frequency). Random-effects 
analysis was used to calculate weighted mean estimates and confidence intervals. 
Heterogeneity was evaluated by statistical tests including I2.
Results: Of 2752 citations reviewed, 17 articles (480 patients) were eligible including 10 
retrospective studies and seven prospective studies. A random-effects model produced 
a pooled proportion of 54% (95% confidence intervals [CI]: 45%, 64%) of patients with 
LGS who responded to adjunctive VNS Therapy (p for heterogeneity <0.001, I2=72.9%). 
Per an exploratory analysis, the calculated incidence of serious adverse events associ-
ated with VNS Therapy was 9% (95% CI: 5%, 14%); the rate was higher than in long-term 
efficacy studies of heterogeneous cohorts with drug-resistant epilepsy and likely attrib-
uted to variable definitions of serious adverse events across studies.
Conclusions: The meta-analysis of 480 patients with LGS suggests that 54% of pa-
tients responded to adjunctive VNS Therapy and that the treatment option was safe 
and well-tolerated. The response in patients with LGS was comparable to heteroge-
neous drug-resistant epilepsy populations. A clinical and surgical overview has been 
included to facilitate the use of VNS in LGS.
K E Y W O R D S
epilepsy, Lennox-Gastaut syndrome, seizures, systematic meta-analysis review, vagus nerve 
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problems. LGS poses a therapeutic challenge, and optimal manage-
ment requires complex antiepileptic treatment strategies while bal-
ancing the side effects of medications and attempting to preserve 
cognitive function.1 Complete seizure control is rarely seen; the res-
olution of intellectual and psychosocial dysfunction is often not fea-
sible. Notably, patients with LGS who received adequate treatment 
very early in their disease process have been documented to have a 
more favorable overall outcome.4,5
VNS Therapy is indicated for use as an adjunctive neuromodu-
latory therapy for reducing the frequency and severity of seizures 
in patients with drug-resistant epilepsy. In Europe, VNS Therapy is 
approved for use in patients of all ages whose epileptic disorder is 
dominated by focal seizures (with or without secondary generaliza-
tion) or generalized seizures. In the United States, VNS Therapy is 
approved in patients who are 4 years of age and older with focal 
onset seizures.
Several studies have evaluated the safety and efficacy of VNS 
Therapy in the treatment of LGS.6–10 Based on a pooled analysis of 
adjunctive VNS Therapy, about 55% of patients with LGS achieved 
>50% reduction in seizure frequency at one to ten years after im-
plantation.6,9,11–13 In this meta-analysis, we examined the clinical ef-
fectiveness of adjunctive VNS Therapy in the treatment of seizures 
in patients with LGS, by analyzing seizure frequency changes after 
VNS Therapy in patients with LGS reported in the literature. We 
have also provided a clinical and surgical overview to facilitate un-
derstanding of the use of VNS Therapy in the treatment of patients 
with LGS.
2  |  METHODS
2.1  |  Search strategy and selection criteria
The present meta-analysis was modeled after the preferred report-
ing items for systematic reviews and meta-analyses (PRISMA) and 
adheres to a structured review protocol not pre-registered in an 
International Prospective Register for systematic reviews. A system-
atic search of the electronic PubMed database of the United States 
National Library of Medicine at the National Institutes of Health was 
performed from January 1997 to September 2018 to identify pub-
lished peer-reviewed original research studies that reported on ef-
ficacy of VNS Therapy in patients with LGS, with or without safety 
findings. There were no restrictions on study design. No language 
restrictions were applied during the search of the PubMed data-
base and the search terms included combinations of (a) VNS, vagal 
nerve stimulation, vagus nerve stimulation, and (b) Lennox-Gastaut, 
LGS. A thorough review of the abstracts from the identified articles 
was independently conducted by two independent reviewers (MD 
and MAK). The reviewers evaluated the quality assessments of the 
eligible clinical studies and assessed the likelihood of bias; any dis-
cordances in the selection process were resolved by consensus and/
or additional referees. Duplicate reporting was excluded from the 
analyses. The complete full-text versions of the remaining articles 
were then reviewed by both reviewers to yield the final pool of arti-
cles included in this analysis.
2.2  |  Data extraction
Baseline, procedural, and outcome data were independently abstracted 
by the two reviewers (MD and MAK). Specifically, potential sources of 
significant clinical heterogeneity, such as study design, single center 
or multicenter, sample size, and follow-up duration, as well as primary 
study endpoints and other key outcomes, have been captured in a data 
extraction table (available from the authors upon request).
2.3  |  Analysis endpoints
The primary endpoint for the meta-analysis was the proportion of 
responders who reported ≥50% reduction in seizure frequency at 
the longest available follow-up period during treatment with adjunc-
tive VNS Therapy. Proportion of serious and mild transient adverse 
events were evaluated as exploratory endpoints.
2.4  |  Statistical analysis
A random-effects meta-analysis was performed to combine study-
specific estimates and to calculate the correspondent weighted 
mean estimate of proportion of responders (≥50% reduction in sei-
zure frequency) for patients with LGS treated with VNS Therapy.
Each pooled estimate was derived by interpolating a ran-
dom-effects model which accommodates the presence of clinical, 
methodological, and statistical heterogeneity. A restricted maxi-
mum-likelihood estimator was used to estimate the between-stud-
ies variance. Fixed-effect model was used as sensitivity analysis to 
confirm the results related to the primary endpoint.
All analyses were conducted using the Freeman-Tukey double 
arcsine transformation of the study-specific proportions14 to stabi-
lize the estimate's variance and to make the normal distribution as-
sumptions more applicable to significance testing. This allowed the 
inclusion of studies with proportions equal to 0 or 100% and avoided 
confidence intervals exceeding the 0 to 1 range. Thereby, studies 
with 0 events or 100% events will contribute to the pooled estimate 
without the use of continuity corrections.
Overall estimates, and the correspondent 95% confidence inter-
vals, were derived from proportion of back-transformations which 
were calculated applying the formula p = sin (2t/2)2, where t rep-
resents the Freeman-Tukey double arcsine of the overall or confi-
dence limits estimates.15
Potential publication bias on transformed proportions of re-
sponder was analyzed using Begg-Mazumdar's rank correlation test 
and the Egger's linear regression test.16,17 Univariate meta-regres-
sion analyses and stratified meta-analyses were performed to ex-
plore the relation between study-specific-transformed proportions 
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of responder and year of publication, longest follow-up available, 
and study design.
Studies included in the meta-analysis were graphically displayed 
by means of forest plots; heterogeneity across studies were assessed 
using Cochran's Q statistics, and the extent of statistical consistency 
was measured with Higgins and Thompson I2 statistics.
Exploratory analysis was performed on the number of partici-
pants with serious adverse events and mild transient adverse events 
and analyzed based on means of a random-effects model.
Statistical significance was set at the two tailed 0.05 level for 
publication bias and meta-regression coefficients, whereas a 0.10 
statistical significance was used for heterogeneity.
3  |  RESULTS
3.1  |  Eligible articles
The original literature search identified 2752 abstracts (Figure 1). Of 
these, 2717 were excluded as they were not relevant (ie, not reporting 
on seizure reduction after VNS Therapy in patients with LGS), leaving 
35 to be examined at full text. Among these, 18 records were excluded 
for one or more of the following reasons: reporting of outcomes after 
combined treatment with VNS and another treatment (eg, corpus cal-
losotomy); potentially duplicate reporting of participants; not includ-
ing original data; not reporting seizure outcomes for patients with LGS 
specifically; and for not reporting on seizure frequency reduction.
The remaining 17 articles reporting original data on seizure 
frequency in 480 patients with LGS who were treated with VNS 
Therapy were included in this meta-analysis (Table 1).7–10,12,18–29 The 
studies were categorized based on their prospective or retrospec-
tive design. One of the articles (Buoni et al.) was conservatively cate-
gorized as a retrospective study as it was not possible to conclusively 
ascertain whether had a prospective or retrospective design.21 As 
such, 10 of the studies were retrospective and seven of the studies 
were conducted prospectively. The included studies were published 
between May 1997 and May 2016. One study received partial sup-
port from the device manufacturer,24 and one study was sponsored 
by the device manufacturer.10
3.2  |  Proportion of responders and 
sensitivity analyses
The pooled proportion (back transformation) of responders (271 
out of 480 participants) produced an estimate of 54% (95% CI: 
45%, 64%) of patients with LGS who responded to adjunctive VNS 
Therapy; proportion = 0.54; 95% CI: 0.45, 0.64; I2 = 72.9%; Q p-value 
for heterogeneity <0.001, based on the random-effects model with 
inclusion of the 17 identified studies (Figure 2).
To assess sensitivity, the mean estimates from pooled propor-
tions across studies and 95% confidence intervals were calculated 
based on both the random-effects model and the fixed-effect model 
(Table S1).
F I G U R E  1  PRISMA diagram showing the numbers of abstracts that were identified, examined at full text, and included in the final meta-
analysis. Of the 2752 abstracts identified in the original search on the effects of VNS Therapy in patients with LGS, 2717 abstracts were 
excluded for not reporting on seizure reduction after VNS Therapy. The remaining 35 articles were examined at full text, and among these, 
18 records were excluded for reasons listed in the diagram, and the remaining 17 articles were included in the meta-analysis
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TA B L E  1  Baseline characteristics of patients in the 17 studies included in the meta-analysis
Author, year Study center Characteristics of study participants with Lennox-Gastaut syndrome
Aldenkamp et al, 2002 19 Single center in the Netherlands; 
prospective design
• Number of participants: 19
• Sex: 21% female
• Age at seizure onset: Mean of 2 years 7 months (range, 0–8 years)
• Known disease etiology include perinatal anoxia (n = 4), dysplasia (n = 2), 
and viral meningoencephalitis (n = 1)
• Duration of epilepsy prior to VNS implant: 8 years 6 months
• Number of participants with prior corpus callosotomy: 0
• Age at VNS device implantation: Mean of 11 years 2 months 
(range, 6 years–19 years)
• Follow-up after VNS implant: 2 years
• Number of responders: 4
Ben-Menachem et al, 
1999 20
Single center in Sweden; prospective 
design
• Number of participants: 8
• Age: Unknown
• Seizure types: generalized tonic-clonic seizures, absence seizures, and 
atonic seizures
• Number of participants with prior corpus callosotomy: 5
• Follow-up after VNS implant: Mean of 20 months (range, 
3 months–5 years 4 months)
• Number of responders: 5
Buoni et al, 2004 21 Single center in Italy from May 1999 
to May 2002; prospective design
• Number of participants: 7
• Sex: 43% female
• Age range at seizure onset: 2 days–12 years
• Severe mental retardation: n = 5
• Known disease etiology: Prenatal rubella (n = 1), 
neurofibromatosis type 1 (n = 1), measles encephalopathy (n = 1), 
complex cerebral malformation (n = 1), and post-radiotherapy 
encephalopathy (n = 1)
• Seizure types: Atonic seizure, atypical absence, complex partial seizure, 
general tonic-clonic seizure (GTCS), myoclonic seizure,
• Number of participants with prior corpus callosotomy: 0
• Duration of epilepsy prior to VNS implant: mean of 13 years (range, 
9–19 years)
• Age at VNS device implant: Mean of 19 years (range, 15–28 years)
• Follow-up after VNS implant: Mean of 22 months (range, 
9 months–3 years)
• Number of responders: 3
Casazza et al, 2006 22 Single center in Italy from October 
1995 to October 2000; 
prospective design
• Number of participants: 4
• Sex: 50% female
• Mean age at seizure onset: 3 years 6 months (4 months–8 years)
• Disease etiology: Unknown (n = 2), perinatal injury (n = 1), and complex 
cerebral malformation (n = 1)
• Number of participants with prior corpus callosotomy: 0
• Follow-up after VNS implant: 4–9 years
• Number of responders: 0
Cersosimo et al, 2011 23 Single center in Italy; prior to 2010; 
retrospective design
• Number of participants: 46
• Sex: 43% female
• Severe mental retardation: n = 7
• Mean duration of epilepsy prior to VNS implant: 10 years 6 months
• Approximate age at VNS device implantation: 13 years 
(range, 5–20 years)
• Follow-up after VNS implant: Mean of 2 years 6 months (range, 
1–9 years)
• Number of responders: 30
Cukiert et al, 2013 18 Single center in Brazil; implanted 
from 2008–2009; prospective 
design
• Number of participants: 20
• Follow-up after VNS implant: 2 years
• Number of responders: 17
(Continues)
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Author, year Study center Characteristics of study participants with Lennox-Gastaut syndrome
Frost et al, 2001 8 Six centers in the United States; 
implanted before December 
1998; retrospective design
• Number of participants: 24
• Follow-up after VNS implant: 6 months
• Number of responders: 14
Hornig et al, 1997 24 Single center in the United States; 
prospective design
• Number of participants: 6
• Known disease etiology: Cryptogenic
• Number of participants with prior corpus callosotomy: 4
• Age at VNS device implantation: Mean of 9 years (range, 6–13 years)
• Follow-up after VNS implant: 2 months–2 years 6 months
• Number of responders: 5
Hosain et al, 2000 25 Single center in the United States; 
study dates are unknown; 
prospective design
• Number of participants: 13
• Sex: 23% female
• Mean age at seizure onset:
• Seizure types: Tonic, atonic, atypical absence, myoclonic, generalized 
tonic-clonic, or complex partial
• Number of participants with prior corpus callosotomy: 3
• Age at VNS device implantation: Mean of 16 years (range, 4–44 years)
• Follow-up after VNS implant: >6 months
• Number of responders: 6
Karceski et al, 2001 7 Data from VNS patient registry; data 
collected prior to April 2001; 
retrospective design
• Number of participants: 167
• Number of participants with prior corpus callosotomy: 23
• Follow-up after VNS implant: 1 year 6 months
• Number of responders: 107
Katagiri et al, 2016 26 Single center in Japan; implanted 
from January 2012-April 2014; 
retrospective study
• Number of participants: 10
• Sex: 60% female
• Age at seizure onset: 13 months (range, 1–37 months)
• Number of participants with prior corpus callosotomy: 10
• Age at VNS device implantation: Mean of 10 years 8 months (range, 
3–30 years)
• Follow-up after VNS implant: 1 year
• Number of responders: 6
Kostov et al, 2009 12 Single center in Norway; implanted 
from 1997–2007; retrospective 
design
• Number of participants: 30
• Sex: 43% female
• Age at seizure onset: median of 1 year 1 month (range, 1 month–7 years)
• Known disease etiology: Perinatal asphyxia (n = 7), cortical malformation 
(n = 5), lissencephaly (n = 2), corpus callosum agenesis (n = 2), 
meningoencephalitis (n = 2), and tuberous sclerosis (n = 1)
• Number of participants with prior corpus callosotomy: 2
• Duration of epilepsy prior to VNS implant: Median of 12 years
• Age at VNS device implantation: Median of 13 years (range, 4–52 years)
• Follow-up after VNS implant: Median of 4 years 4 months (range, 1 year 
5 months–10 years 3 months)
• Number of responders: 20
Mikati et al, 2009 27 Single center in Lebanon; implanted 
from August 2003 to November 
2007; prospective design
• Number of participants: 6
• Sex: 67% female
• Age at seizure onset: mean of 5 years 1 month (range, 9 months–9 years)
• Known disease etiology: Cryptogenic
• Seizure types: Generalized, atonic, absence, generalized tonic-clonic, and 
myoclonic
• Number of participants with prior corpus callosotomy: Unknown
• Age at VNS device implant: Mean of 23 years (range, 11–38 years)
• Follow-up after VNS implant: 1 year 11 months (range, 8 months–3 years 
11 months)
• Number of responders: 3
TABLE 1 (Continued)
(Continues)
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3.3  |  Evaluation of publication bias
A funnel plot was generated—based on Freeman-Tukey double 
arcsine transformation of study-specific proportions—to assess 
publication bias of the estimate response rate. For the response 
rate, the asymmetry in the funnel plot was minimal (Figure S1). 
The absence of publication bias on responder proportions was 
further confirmed by the Begg-Mazumdar's rank correlation test 
(Kendall's tau = −0.07, p-value =0.7) and the Egger's linear regres-
sion test (regression coefficient = −0.67 [95% CI −2.65, 1.32], 
p-value = 0.5).
Stratified meta-analyses were performed to provide an esti-
mate of the proportion of responders by retrospective or prospec-
tive design. Table S2 shows the results based on the random-effects 
model to calculate mean estimates from pooled proportions (back 
transformation) across the studies with retrospective versus 
prospective design. Responder rate was not affected by study 
design: n = 10, proportion = 0.56 (95% CI: 0.47, 0.66) and n = 7, 
proportion = 0.50 (95% CI: 0.28, 0.72) for the retrospective and 
prospective studies, respectively (Figures S2 and S3).
3.4  |  Appraisal of heterogeneity
Univariate meta-regression analyses were performed, based on 
Freeman-Tukey double arcsine transformation of study-specific 
proportions, to explore the relation between study-specific propor-
tions and both year of publication and longest follow-up available.
There were no significant effects for year of publication (n = 17, 
slope coefficient =0.001; 95% CI: −0.017, 0.020; p-value =0.9) (Figure 
S4) and length of study follow-up (n = 17, slope coefficient = −0.002; 
95% CI: −0.007, 0.003; p-value =0.5) (Figure S5).
Author, year Study center Characteristics of study participants with Lennox-Gastaut syndrome
Orosz et al, 2014 10 Multiple centers in the European 
Union; retrospective design
• Number of participants: 87
• Sex: ~47% female
• Age at seizure onset: Range, 1 month–9 years 6 months
• Age at VNS device implantation: Range, approximately 2–18 years
• Follow-up after VNS implant: 2 years
• Number of responders: 34
Shahwan et al, 2009 28 Single center in Australia; implanted 
from August 1998 to August 
2006; retrospective design
• Number of participants: 9
• Disease etiology: Cryptogenic (n = 5), tuberous sclerosis (n = 2), 
lissencephaly (n = 1), and B12 deficiency (n = 1)
• Seizure types: Tonic drops, tonic-clonic, status epilepticus; spasms
• Age at VNS device implant: Mean of 10 years 6 months (range, 4 years 
6 months–15 years 4 months)
• Follow-up after VNS implant: 3 years 10 months (range, 1 year 
10 months–8 years 6 months)
• Number of responders: 7
You et al, 2008 9 Multiple centers in South Korea; 
implanted between July 1995-
March 2005; retrospective 
design
• Number of participants: 10
• Sex: 60% female
• Age at seizure onset: 2 years (range, 1 month–8 years 2 months)
• Seizure types: Tonic or atonic head-drop, myoclonic, generalized tonic, 
and generalized tonic-clonic
• Number of participants with prior corpus callosotomy: 0
• Duration of epilepsy prior to VNS implant: 8 years 8 months (range, 
1 year 4 months–17 years 10 months)
• Follow-up after VNS implant: 2 years 10 months (range, 1–6 years 
11 months)
• Number of responders: 7
Zamponi et al, 2011 29 Single center in Italy; data collected 
from 2000–2008; retrospective 
design
• Number of participants: 14
• Sex: 29% female
• Disease etiology: Cryptogenic (n = 10) and perinatal anoxia (n = 3)
• Seizure types: Drop attacks, generalized, tonic, spasms, partial, and 
myoclonic
• Number of participants with prior corpus callosotomy: 0
• Age at VNS device implantation: Mean of 13 years 10 months (range, 
5 years 5 months–25 years)
• Follow-up after VNS implant: 3 years (range, 3–8 years 2 months)
• Number of responders: 3
VNS, Vagus Nerve Stimulation.
TABLE 1 (Continued)
    |  7DIBUÉ et al.
3.5  |  Exploratory safety analysis
The proportion of participants with serious adverse events and 
mild transient adverse events were analyzed based on means of a 
random-effects model. The pooled proportion (back transforma-
tion) of participants with serious adverse events was an estimate of 
0.09 (95% CI: 0.05, 0.014) with 11 studies included (I2 = 0%; Q p-
value = 0.4), and the proportion of participants with mild transient 
adverse events was an estimate of 0.33 (95% CI: 0.15, 0.54) with six 
studies included (I2 = 76.3%; Q p-value <0.001), respectively (Table 
S3).
Figure 3 and Figure S6, respectively, report the forest plots of 
studies that reported serious adverse events (11 studies) and mild 
transient adverse events (6 studies).
Eight cases of death were reported in the included studies: one 
due to cancer, one due to pneumonia, three due to SUDEP and three 
due to status epilepticus. Two cases of SUDEP were not included in 
the serious adverse events analysis, as they did not occur in patients 
with LGS. The deaths due to pneumonia and cancer were also not 
included in the analysis due to these events not being considered 
potential adverse events of VNS Therapy. The remaining 4 deaths 
(1 SUDEP and 3 status epilepticus)—all reported in one study—were 
included in the serious adverse analysis.
4  |  DISCUSSION
This meta-analysis of 17 articles comprising 480 patients with LGS 
found 54% of patients to experience more than 50% seizure fre-
quency reduction after treatment with vagus nerve stimulation. 
Furthermore, exploratory analysis of adverse events associated with 
VNS Therapy in patients with LGS calculated an incidence of serious 
adverse events of 9% from 11 studies, and an incidence of mild tran-
sient adverse events of 33% from 6 studies. Serious adverse events 
included 4 deaths: 1 due to SUDEP and 3 due to status epilepticus. 
An incidence rate for epilepsy-related mortality or SUDEP in patients 
with LGS could not be calculated in this analysis as patient years of 
VNS Therapy in LGS patients were not reported in the included stud-
ies. Mortality and SUDEP rates for all patients receiving VNS Therapy 
in the United States have been published by Ryvlin et al in 2017 who 
found all-cause mortality rates of 13.1 per 1000 patient years and 
SUDEP rates of rates of 2.47 and 1.68 per 1000 patient years of VNS 
F I G U R E  2  Forest plot displaying a random-effects meta-analysis (RE Model) of the primary endpoint. The 17 studies included in the 
analysis are listed in alphabetical order by the last author and publication year. The size of the square box is proportional to the weight that 
each study contributes to the meta-analysis, and the overall estimate is marked by a diamond. The primary endpoint was the proportion 
of responders (Resp.) among patients who received adjunctive VNS Therapy (VNS) who reported ≥50% reduction in seizure frequency 
(Response Rate=Resp./VNS) at the longest available follow-up period during treatment with adjunctive VNS Therapy. A total of 271 out 
of 480 patients responded to treatment. The pooled proportion (using the double arcsine back transformation) of responders produced 
weighted effects size (ES) estimates for each study. The mean estimated proportion demonstrates that 0.54 of patients with LGS responded 
with adjunctive VNS Therapy (95% CI: 0.45, 0.64; Cochran's Q = 53.3; degrees of freedom [df] =16; Qp-value for heterogeneity <0.001; 
I2 = 72.9%)
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Therapy in years 1–2 and in years 3–10, respectively. All-cause mor-
tality and SUDEP rates of VNS Therapy have yet to be reported for 
patients with LGS specifically; however, mortality and SUDEP rates in 
the full US VNS population reported in Ryvlin et al 2017 suggest that 
VNS Therapy is associated with similar mortality rates as reported for 
patients with drug-resistant epilepsy without VNS and that SUDEP 
rates may decline in the course of therapy.
The majority of the included studies are case series of 10–50 pa-
tients with different epilepsy etiologies in which patients with LGS 
represent the largest subgroup, possibly reflecting the frequent use 
of VNS Therapy in this patient population. In Orosz et al.'s retro-
spective multicenter analysis of 347 pediatric patients treated with 
VNS Therapy, which remains the largest analysis of VNS Therapy 
in children to date, LGS represented the largest subgroup in the 
study with 87 children. Orosz et al found a 39% responder rate for 
LGS patients at 24 months which was comparable to the 43.8% re-
sponder rate calculated for the full population at 24 months. The 
largest trial included in our analysis, Karceski et al 2001 found the 
noticeably higher responder rate of 64% in this cohort of adults and 
children with LGS treated with VNS Therapy. This analysis of all pa-
tients with LGS the VNS Patient Registry in the United States in-
cluded 552 patients with LGS treated with VNS Therapy. However, 
responder rates were only reported for a fraction of these patients 
and therefore only these 167 could be included in the present anal-
ysis. The study did however analyze patients with LGS who had 
previous callosotomy separately from those who did not, but found 
no striking difference in responder rate between the two groups at 
12 months of follow-up (57% in patients with prior callosotomy vs. 
65% without prior callosotomy). The third largest study included in 
the present analysis comprising 46 patients with LGS with a mean 
age of 13 years (range: 5–19.5 years) found a 65% responder rate. 
In this analysis, Cersosimo et al classify outcomes by McHugh clas-
sification offering greater granularity into the effects of VNS in LGS 
patients. The McHugh classification is adapted from the Engels clas-
sification for epilepsy surgery outcomes and is a specific classifier 
for seizure burden after VNS Therapy. Cersosimo et al report that 
61% of LGS patients treated with VNS Therapy experienced a class 
1A outcome meaning that that they experienced 80%-100% seizure 
frequency reduction and a reduction in ictal or post-ictal severity.
4.1  |  Integration of VNS into a treatment algorithm 
for LGS
Patients with LGS experience several types of seizures includ-
ing atypical absences, tonic postural seizures, tonic seizures, and 
F I G U R E  3  Forest plot displaying a random-effects meta-analysis (RE Model) of serious adverse events (SAEs) reported for each 
study. The 11 studies with relevant data are listed in alphabetical order by the last author and publication year. The size of the square 
box is proportional to the weight that each study contributes to the meta-analysis and the overall estimate is marked by a diamond. The 
proportion of patients who experienced SAEs among patients who received adjunctive VNS Therapy (VNS) is presented (Rate = SAEs/
VNS). A total of 10 out of 149 patients experienced serious adverse events and the pooled proportion (using the double arcsine back 
transformation) produced weighted effects size (ES) estimates and 95% confidence interval (CI) for each study. The mean estimated 
proportion demonstrates that 0.09 of patients with LGS experienced serious adverse events with adjunctive VNS Therapy (95% CI: 0.05, 
0.14; Cochran's Q = 10.49; degrees of freedom [df] =10; Qp-value for heterogeneity = 0.40; I2 = 0.0%)
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generalized tonic-clonic seizures; and a single treatment is not likely 
to be effective in treating such a seizure spectrum. Due to their com-
plex seizure types and poor response to AEDs, patients with LGS are 
difficult to treat and often require polypharmacy of high doses of 
AEDs which is associated with a high side-effect burden. This may 
elicit or aggravate cognitive and behavioral problems which repre-
sents an additional burden for patients and caregivers.
Treatment is usually initiated with one or more antiepileptic 
drugs (AEDs) and progresses over time to a polypharmacy of AEDs. 
Adjunctive treatment with non-pharmacological options are con-
sidered when seizure control is not achieved with AEDs, and the 
non-pharmacological treatment options include ketogenic diet, re-
sective surgery, corpus callosotomy, and VNS1,30
The ketogenic diet has been shown to be efficacious in the treat-
ment of LGS with 47% to 51% of pediatric patients achieving >50% 
reduction in seizure frequency following 3–36 months of ketogenic 
diet therapy.1,31 This adjunctive dietary therapy (and other related 
dietary therapies such as modified Atkins or low-glycemic index) can 
offer increased seizure control with a rapid onset effect, usually ob-
served within 3 months. Effective therapy with the ketogenic diet 
requires compliant patients and dedicated caregivers and as such, 
long-term treatment adherence is one of the major issues with the 
ketogenic diet.1
Resective surgery is a treatment option in LGS patients with focal 
pathology and there is a high probability of seizure control in about 
50% of patients following surgery.32 Patients are carefully identi-
fied for resective surgery based on congruent findings of a defin-
itive structural lesion using electroencephalogram (EEG), magnetic 
resonance imaging (MRI), and functional neuroimaging. Patients 
without identifiable localized brain lesion can be re-evaluated after 
treatment with VNS Therapy or corpus callosotomy, when general-
ized epileptiform discharges may become more localized. Generally, 
resective surgery is only indicated in focal pathology rendering it 
unsuitable for a majority of LGS patients.
Corpus callosotomy is considered in patients with LGS who are 
experiencing frequent debilitating drop seizures, which are mostly 
atonic in nature. Corpus callosotomy has been found to be more ef-
fective in reducing the frequency of atonic seizures in LGS patients 
compared with VNS Therapy; and in contrast, the same study found 
VNS Therapy to be more effective in reducing myoclonic seizures 
compared with corpus callosotomy.18 Both corpus callosotomy and 
VNS Therapy appear to have similar effectiveness in reducing other 
seizure types in LGS patients; however, corpus callosotomy includes 
risks associated with craniotomy as well as a risk of disconnection 
syndrome.1,33
In the 2017 Expert Consensus on LGS treatment,1 Cross 
et al highlighted the importance of patient-centered therapeutic 
approaches; for example, focusing on treating the most disabling 
seizure type (which may vary among patients and be highly de-
pendent on their living situation) instead of seizure freedom. Cross 
et al also stressed that clinicians should focus on the overall quality 
of life when considering therapy for LGS and be vigilant about the 
negative impact of adverse drug effects on patients’ quality of life. 
Furthermore, the expert consensus recommended early integration 
of non-pharmacological treatments into LGS treatment strategies, 
including VNS Therapy.
VNS Therapy may be a valuable option that might increase sei-
zure control in LGS patients together with a reduction of medication 
burden (as evidenced in patients with drug-resistant epilepsy34) and 
improvement of the cognitive and behavioral consequences associ-
ated with multiple AEDs administration.
Results from our meta-analysis suggests that adjunctive VNS 
Therapy is effective in reducing seizure burden in patients with LGS 
and the seizure reduction is comparable to that observed in hetero-
geneous drug-resistant epilepsy populations.35 Therefore, it is rel-
evant to consider the optimal positioning of VNS Therapy within a 
treatment algorithm for LGS and patients with LGS should be care-
fully evaluated for VNS Therapy implantation before more invasive 
palliative surgical procedures.
4.2  |  Exploratory analysis of safety findings
The incidence of serious adverse events associated with VNS in pa-
tients with LGS in this analysis (9%; 95% CI: 5%, 14%) was higher than 
reported in long-term efficacy studies of heterogeneous cohorts 
with drug-resistant epilepsy (1.4%–2.4%).36,37 This may potentially 
be attributed to variances in definition of serious and mild transient 
adverse events across the included studies. For example, due to in-
complete reporting on treatment of infection in some of the included 
studies, any infection had to be considered a serious adverse event 
in this analysis, irrespective of whether it could be treated conserva-
tively or required device removal, whereas other trials consider infec-
tion not requiring device removal a mild adverse event.
4.3  |  Clinical and surgical considerations related to 
VNS therapy device implantation in patients with LGS
Here a clinical and surgical overview to facilitate understanding of 
the use of VNS Therapy in the treatment of patients with LGS is 
provided.
Similar to neurosurgical shunt surgeries, implanting a VNS Therapy 
pulse generator and silicone leads benefits from a standardized repro-
ducible approach that ensures a quick procedure, minimizes errors, 
and has a low infection risk. As the surgery involves implanting a cor-
pus alienum, there is generally a greater than average risk of infection; 
however, based on analysis of VNS implantation surgeries performed 
between 2005 and 2016, the procedure has a post-operative infection 
risk of 1.3% which is within the normal range per the guidelines from 
the American College of Surgeons and Surgical Infection Society.38–40
VNS device implantation is performed under general anesthesia 
with the patient in supine position with the head slightly extended. 
After sterile prep and drape, a skin crease neck incision is placed. 
Platysma is divided, followed by subplatysmal dissection in cranial 
and caudal direction. The cervical section of the vagus nerve runs 
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within the carotid sheet in a parallel course along the carotid artery. 
However, the position varies between patients and in a minority of 
patients, the vagus nerve is localized dorsomedially between the 
carotid artery and internal jugular vein as stated in textbooks.41,42 
Ultrasound is an easy and non-invasive method of localizing the 
vagus nerve prior to and during surgery; the carotid is a round pul-
sating non-compressible structure, the jugular vein is lateral to this 
and is more oval shaped and easily compressible. Similar to other 
nerves, the vagus nerve appears dark on ultrasound and its course 
continues to be parallel to the carotid.
Implanting a VNS Therapy device consists of three steps: place-
ment of the electrode contacts around the vagus nerve, tunneling of 
the leads, and placement of the pulse generator. The order in which 
this is done varies between surgeons; however, it is advisable to per-
form the steps in the listed standardized order.43
In order to obtain a clear interface between contacts and the vagus 
nerve for optimal VNS Therapy response, the vagus nerve needs to be 
well dissected from its surrounding tissues without compromising the 
nerve or the surrounding vasculature and exiting branches.
The pocket for the implantable pulse generator (IPG) is created 
in the left pectoral region. Subcutaneous placement of the generator 
right on top of the musculus pectoralis fascia instead of a sub-fascial 
placement is practical and less invasive and ensures optimal commu-
nication between the IPG and the VNS Therapy programming sys-
tem. However in some patients, auto-manipulation of the wound or 
tampering with the IPG after wound healing (“twiddling”) may be a 
concern.44 This may be specifically relevant in patients with LGS in 
the case of significant cognitive impairment, autistic traits, and be-
havioral problems. Sub-fascial placement may then be beneficial as 
the deep localization makes it less prone to displacement and infec-
tion. Interscapular placement may be considered45; however, it is im-
portant to note that this will likely impair the use of the cardiac-based 
seizure detection feature of responsive VNS Therapy generators, as 
these devices rely on continuous monitoring of the electrocardio-
gram (ECG) measured as the vector between the electrodes and the 
IPG positioned in a pectoral location. Interscapular placement of the 
IPG will alter QRS morphology which may prevent correct detection 
by the cardiac-based seizure detection algorithm. Hence, before in-
terscapular placement, it should be considered whether the patient 
is significantly impaired by a seizure type associated with ictal tachy-
cardia, which may potentially be aborted or reduced in intensity by 
responsive VNS Therapy. Furthermore, in order to prevent migration 
of the generator it should be anchored to the fascia, which again may 
be of extra importance in patients with LGS.
As with all neurostimulation devices, after connecting the IPG 
to the electrodes and before wound closure, acceptable impedance 
should be confirmed. Additionally, in responsive VNS Therapy de-
vices, correct sensing of the ECG should be confirmed, as incorrect 
sensing may require repositioning of the IPG.
Absolute hemostasis is secured and both wounds are closed 
in layers. Wound drains are not typically placed in this procedure. 
Incision sites are dressed with waterproof dressing and patients are 
commonly discharged on the same day of surgery or the next day.38
Malfunction due to (partial) lead break is a known possible 
long-term complication in VNS, especially with the older model 
of more flexible leads. In patients with LGS, such a malfunction 
can easily lead to status epilepticus with devastating effects.46 
Therefore, if indicated the patient should be swiftly advanced 
to revision surgery in which assuring the integrity of the vagus 
nerve is always the primary goal. If needed, the fractured elec-
trode can be cut below the helices and left in place and the new 
electrodes placed along an adjacent section of the vagus nerve. 
In general, a complete removal can be safely achieved in which 
the use of microsurgical techniques and the microscope are highly 
recommended.47,48
4.4  |  Strengths and limitations
This report represents the most comprehensive meta-analysis of 
VNS Therapy in LGS patients and has prospectively analyzed po-
tential sources of bias that often negatively impact analyses of this 
nature. However, the results reported here is limited by the inherent 
property of meta-analyses of ignoring potentially important differ-
ences across studies as well as by the low patient-level insight in the 
identified studies. Furthermore, some of the included studies have 
small sample sizes and only meet American Academy of Neurology 
Class III evidence criteria for therapeutic studies.
5  |  CONCLUSIONS
LGS is a severely drug-resistant epileptic syndrome. As patients with 
LGS who receive adequate treatment very early in their disease pro-
cess have been documented to have a more favorable overall out-
come, the early integration of VNS Therapy should be considered 
as it may improve the negative consequences of both seizures and 
epileptic abnormalities. This meta-analysis suggests that VNS is a 
well-tolerated and effective adjunctive treatment for patients with 
LGS resulting in a responder proportion of 54% (95% CI: 45%, 64%), 
which is comparable to response in heterogeneous drug-resistant 
epilepsy populations. VNS Therapy may be a valuable treatment to 
increase seizure control in patients with LGS, and patients with LGS 
should be carefully evaluated for VNS Therapy implantation before 
more invasive palliative surgical procedures.
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